» Articles » PMID: 27994508

CRISPR-Cas9: from Genome Editing to Cancer Research

Overview
Journal Int J Biol Sci
Specialty Biology
Date 2016 Dec 21
PMID 27994508
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer development is a multistep process triggered by innate and acquired mutations, which cause the functional abnormality and determine the initiation and progression of tumorigenesis. Gene editing is a widely used engineering tool for generating mutations that enhance tumorigenesis. The recent developed clustered regularly interspaced short palindromic repeats-CRISPR-associated 9 (CRISPR-Cas9) system renews the genome editing approach into a more convenient and efficient way. By rapidly introducing genetic modifications in cell lines, organs and animals, CRISPR-Cas9 system extends the gene editing into whole genome screening, both in loss-of-function and gain-of-function manners. Meanwhile, the system accelerates the establishment of animal cancer models, promoting studies for cancer research. Furthermore, CRISPR-Cas9 system is modified into diverse innovative tools for observing the dynamic bioprocesses in cancer studies, such as image tracing for targeted DNA, regulation of transcription activation or repression. Here, we view recent technical advances in the application of CRISPR-Cas9 system in cancer genetics, large-scale cancer driver gene hunting, animal cancer modeling and functional studies.

Citing Articles

Advances in delivery systems for CRISPR/Cas-mediated cancer treatment: a focus on viral vectors and extracellular vesicles.

Song Z, Tao Y, Liu Y, Li J Front Immunol. 2024; 15:1444437.

PMID: 39281673 PMC: 11392784. DOI: 10.3389/fimmu.2024.1444437.


Mapping the global landscape for induced pluripotent stem cells from patents and clinical trials.

Lyu L, Feng Y, Huang B, Xu R, Hu Y Nat Biotechnol. 2024; 42(4):563-569.

PMID: 38632441 DOI: 10.1038/s41587-024-02196-1.


Developing hydrogels for gene therapy and tissue engineering.

Su C, Lin D, Huang X, Feng J, Jin A, Wang F J Nanobiotechnology. 2024; 22(1):182.

PMID: 38622684 PMC: 11017488. DOI: 10.1186/s12951-024-02462-z.


CRISPR-Based Gene Editing: a Modern Approach for Study and Treatment of Cancer.

Talukder P, Chanda S, Chaudhuri B, Choudhury S, Saha D, Dash S Appl Biochem Biotechnol. 2023; 196(7):4439-4456.

PMID: 37737443 DOI: 10.1007/s12010-023-04708-2.


Accelerated Apoptosis and Down-Regulated FMRP in Human Neuroblastoma Cells with CRISPR/ Genome Editing.

Zhang R, Xu H, Lu J, Chen Y, Zhang Y, Xiao L Iran J Public Health. 2023; 52(4):703-712.

PMID: 37551173 PMC: 10404333. DOI: 10.18502/ijph.v52i4.12438.


References
1.
Schramek D, Sendoel A, Segal J, Beronja S, Heller E, Oristian D . Direct in vivo RNAi screen unveils myosin IIa as a tumor suppressor of squamous cell carcinomas. Science. 2014; 343(6168):309-13. PMC: 4159249. DOI: 10.1126/science.1248627. View

2.
Song M, Salmena L, Pandolfi P . The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012; 13(5):283-96. DOI: 10.1038/nrm3330. View

3.
Barrangou R, May A . Unraveling the potential of CRISPR-Cas9 for gene therapy. Expert Opin Biol Ther. 2014; 15(3):311-4. DOI: 10.1517/14712598.2015.994501. View

4.
Garraway L, Lander E . Lessons from the cancer genome. Cell. 2013; 153(1):17-37. DOI: 10.1016/j.cell.2013.03.002. View

5.
Rastogi A, Murik O, Bowler C, Tirichine L . PhytoCRISP-Ex: a web-based and stand-alone application to find specific target sequences for CRISPR/CAS editing. BMC Bioinformatics. 2016; 17(1):261. PMC: 4929763. DOI: 10.1186/s12859-016-1143-1. View